Natural herbal medicine lianhuaqingwen capsule anti-influenza a (H1N1) trial: A randomized, double blind, positive controlled clinical trial

Chinese Medical Journal

Volumn 124, Issue 18, 2011, Pages 2925-2933

  Duan, Zhong Ping ^a   Jia, Zhen Hua ^b   Zhang, Jian ^b   Liu, Shuang ^a   Chen, Yu ^a   Liang, Lian Chun ^a   Zhang, Chang Qing ^c   Zhang, Zong ^d   Sun, Yan ^e   Zhang, Shu Qin ^f   Wang, Yong Yan ^g   Wu, Yi Ling ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Hebei Yiling Academy of Medicine   (China)

^c Kaifeng Infectious Disease Hospital   (China)

^d JINAN INFECTIOUS DISEASE HOSPITAL   (China)

^e Henan Provincial Infectious Disease Hospital   (China)

^f Jilin Provincial Hepatopathy Hospital   (China)

^g INSTITUTE OF CHINESE MATERIA MEDICA   (China)

Author keywords

Clinical randomized controlled trial; Influenza a (H1N1); Lianhuaqingwen capsule

Indexed keywords

HERBACEOUS AGENT; LIANHUAQINGWEN; OSELTAMIVIR; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AGED; ARTICLE; AXILLA TEMPERATURE; CHILL; CLINICAL OBSERVATION; CONTROLLED STUDY; COUGHING; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HERBAL MEDICINE; HUMAN; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA AND VOMITING; NOSE CONGESTION; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHINORRHEA; SORE THROAT; SWEATING; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS SHEDDING;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053027494     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.18.024     Document Type: Article

References (34)

1. DG statement following the meeting of the Emergency Committee. Geneva: World Health Organization, 2009. (Accessed June 11, 2009 at http://www.who.int/csr/disease/swineflu/4th_meeting_ihr/en/index.htm.)
2. Centers for Disease Control and Prevention (CDC). Swine influenza A (H1N1) infection in two children, Southern California, March-April 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 400-402.
3. Swine influenza update 5. Geneva: World Heath Organization, 2009. (Accessed December 18, 2009 at http://www.who.int/csr/don/2009_04_29/en/index.html.)
4. WHO technical consultation on the severity of disease caused by the new influenza A (H1N1) virus infections. Original short summary posted May 6 2009. Revised full report posted May 9 2009. Geneva: World Heath Organization, 2009. (Accessed December 18, 2009 at http://www.who.int/csr/resources/publications/swineflu/technical_consultation_2009_05_06/en/index.html.)
5. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360: 2605-2615.
6. Pandemic (H1N1) 2009 update 79. Geneva: World Heath Organization, 2009. (Accessed December 18, 2009 at http://www.who.int/csr/don/2009_12_18a/en/index.html.)
7. Mossad SB. The resurgence of swine-origin influenza A (H1N1). Cleve Clin J Med 2009; 76: 337-343.
8. Petrosillo N, Di Bella S, Drapeau CM, Grilli E. The novel influenza A (H1N1) virus pandemic: an update. Ann Thorac Med 2009; 4: 163-172.
9. France sells off surplus swine flu vaccine. BBC. One-minute world news. January 3, 2010 (Accessed January 5, 2010 at http://news.bbc.co.uk/2/hi/health/8438663.stm)
10. Centers for Disease Control and Prevention (CDC). Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 433-435.
11. Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009-2010 season. Atlanta: Centers for Disease Control and Prevention, 2009. (Accessed December 18, 2009 at http://www.cdc.gov/h1n1flu/recommendations.htm)
12. Lackenby A, Hungnes O, Dudman SG, Meijer A, Paget WJ, Hay AJ, et al. Emergence of resistance to Oseltamivir among influenza A (H1N1) viruses in Europe. Euro Surveill 2008; 13. Pii: 8026.
13. Centers for Disease Control and Prevention (CDC). Update influenza activity - United States, September 28, 2008-January 31, 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 115-119.
14. Centers for Disease Control and Prevention (CDC). Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients, Seattle, Washington, 2009. MMWR Morb Morta Wkly Rep 2009; 58: 893-896.
15. Wang YT, Chan CH, Su ZY, Chen CL. Homology modeling, docking, and molecular dynamics reveals HR1039 as a potent inhibitor of 2009 A (H1N1) influenza neuraminidase. Biophys Chem 2010; 147: 74-80.
16. The guideline for the surveillance, reporting, diagnosis, and treatment of pandemic (H1N1) 2009. Beijing: Ministry of Health of the People's Republic of China, 2009. (Accessed December 18, 2009 at http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohyzs/s3585/200905/40478.htm.)
17. Hsu CH, Hwang KC, Chao CL, Chang SGN, Ho MS, Lin JG, et al. An evaluation of the additive effect of natural herbal medicine on SARS or SARS-like infectious diseases in 2003: a randomized, double-blind, and controlled pilot study. Evid Based Complement Alternat Med 2008; 5: 355-362.
18. Liu GX, Zhang YX, Yang JQ, Gao ZQ, Meng YC. The randomized controlled study of Lianhuaqingwen capsule in treating A/H1N1 influenza. Chin J Diffic Ccompl Dis (Chin) 2010; 1: 14-16.
19. The Guideline for the surveillance, reporting, diagnosis, and treatment of pandemic (H1N1) 2009 (the third edition). Beijing: Ministry of Health of the People's Republic of China. (Accessed October 13, 2009 at http://61.49.18.65/publicfiles/business/htmlfiles/mohyzs/s3586/200910/43111.htm)
20. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, et al. Efficacy and safety of the oral neuraminidase inhibitor Oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000; 283: 1016-1024.
21. Hollander M, Wolfe DA. Nonparametric statistical methods. New York: John Wiley & Sons; 1973: 75-82.
22. Points to consider on missing data. EMEA: Committee for Proprietary Medicinal Products, 2001. (Accessed September 20, 2009 at http://www.emea.eu.int/pdfs/human/ewp/177699EN.pdf.)
23. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infec Dis 2009; 48: 3-13.
24. Jefferson T, Di Pietrantonj C, Debalini MG, Rivetti A, Demicheli V. Inactivated influenza vaccines: methods, policies, and politics. J Clin Epidemiol 2009; 62: 677-686.
25. Lackenby A, Thompson CI, Democratis J. The potential impact of neuraminidase inhibitor resistant influenza. Curr Opin Infect Dis 2008; 21: 626-638.
26. Cheng PK, Leung TW, Ho EC, Leung PC, Ng AY, Lai MY, et al. Oseltamivir- and amantadine-resistant influenza viruses A (H1N1). Emerg Infect Dis 2009; 15: 966-968.
27. Palamara AT, Nencioni L, Aquilano K, De Chiara G, Hernandez L, Cozzolino F, et al. Inhibition of influenza virus replication by resveratrol. J Infect Dis 2005; 191: 1719-1729.
28. Wang X, Jia W, Zhao A, Wang X. Anti-influenza agents from plants and traditional Chinese medicine. Phytother Res 2006; 20: 335-341.
29. Ehrhardt C, Hrincius ER, Korte V, Mazur I, Droebner K, Poetter A, et al. A polyphenol rich plant extract, CYSTUS052, exerts anti influenza virus activity in cell culture without toxic side effects or the tendency to induce viral resistance. Antiviral Res 2007; 76: 38-47.
30. Droebner K, Ehrhardt C, Poetter A, Ludwig S, Planz O. CYSTUS052, a polyphenol-rich plant extract, exerts anti-influenza virus activity in mice. Antiviral Res 2007; 76: 1-10.
31. Human infection with new influenza A (H1N1) virus: clinical observations from a school-associated outbreak in Kobe, Japan, May 2009. Wkly Epidemiol Rec 2009; 84: 237-244.
32. Cao B, Li XW, Mao Y, Wang J, Lu HZ, Chen YS, et al. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med 2009; 361: 2507-2517.
33. Centers for Disease Control and Prevention (CDC). Swine-origin influenza A (H1N1) virus infections in a school - New York City, April 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 470-472.
34. Witkop CT, Duffy MR, Macias EA, Gibbons TF, Escobar JD, Burwell KN, et al. Novel influenza A (H1N1) outbreak at the US air force academy: epidemiology and viral shedding duration. Am J Prev Med 2009; 38: 121-126.